ROCKVILLE, Md., Dec. 4, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Chinese State Intellectual Property Office (SIPO) has issued a patent for a key peptide fragment of Thymosin beta 4 (TB4) to RegeneRx. The patent claims are directed to both composition of matter and methods of use, including suppressing inflammation, stimulating cell migration, protecting tissue from cytotoxicity, inhibiting apoptosis, inhibiting tissue damage caused by UV radiation, and stimulating elastin, among others. The patent expiry is expected to be in 2029.
"This is one of two biologically active peptide fragments of TB4 that we are interested in because, as demonstrated in a number of animal models, we believe they have properties potentially useful in medical and cosmeceutical product candidates. We are pleased that we received this patent in China, which has significant market potential for such products," stated Dr. Allan L. Goldstein, Emeritus Professor and Chairman of the Department of Biochemistry and Molecular Medicine at The George Washington University School of Medicine and RegeneRx's chief scientific advisor.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world. RGN-259, the Company's TB4-based ophthalmic drug candidate, has been designated an orphan drug in the U.S. for the treatment of neurotrophic keratopathy (NK). In September 2015, RegeneRx, through its U.S joint venture, ReGenTree LLC, initiated a Phase 2/3 clinical trial in patients with dry eye syndrome and a Phase 3 clinical trial in patients with NK. Both trials are being conducted in the U.S. and are estimated to be completed in early 2016. RGN-259 will also be tested in patients with dry eye syndrome in Asia through RegeneRx's two Asian partnerships. RGN-352, the Company's TB4-based injectable formulation, is a Phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar traumatic injuries. For additional information about RegeneRx please visit www.regenerx.com.
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can be no assurance that any issued patents or licenses held by the Company or patent applications filed by the Company, including this most recent patent for a peptide fragment of Thymosin beta 4 (TB4) in China or any other country, or any current or future clinical trials will result in approved products or future value. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2014, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
SOURCE RegeneRx Biopharmaceuticals, Inc.